Press Releases

October 1, 2022 Lupin gets EIR from US FDA for its Ankleshwar Manufacturing Facility

September 29, 2022 Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

September 29, 2022 Lupin Launches Sildenafil for Oral Suspension in the United States

September 22, 2022 Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

September 13, 2022 Lupin Receives Health Canada Approval for Rymti® (biosimilar Etanercept)

September 9, 2022 Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

September 7, 2022 Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines

August 29, 2022 Lupin Receives Tentative Approval from U.S. FDA for Dasatinib Tablets

August 26, 2022 Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States